In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Paratek Pharmaceuticals, Inc.

http://paratekpharma.com/

Latest From Paratek Pharmaceuticals, Inc.

Gene Editing Excels As Regenerative Medicine Reaches Record Investments

Gene and cell-based therapeutics attracted the bulk of regenerative medicine investment last year, with gene-editing approaches garnering confidence following key clinical milestones, new research shows.

Financing Gene Therapy

5 Dealmaking Trends To Watch In 2022

2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?

Deals Companies

Up, Up And Away: A Comparison Of Industry R&D Spend Now Versus 10 Years Ago

Average R&D spending by the top 25 biopharma companies increased as a percent of sales from 14.4% in 2010 to 17% in 2020, according to an EY report.

Research & Development Clinical Trials

Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition

AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Novacea, Inc.
    • Transcept Pharmaceuticals, Inc.
    • TransOral Pharmaceuticals, Inc.
UsernamePublicRestriction

Register